Probiotics have long been proposed as a way to soften these side effects, potentially by attenuating antibiotic-induced disruption of the gut microbiota, reinforcing colonization resistance, and modulating mucosal immune responses. Previous meta-analyses, however, pooled trials that mixed proton pump inhibitors, vonoprazan, and other acid suppressants with different antibiotic backbones, probiotic strains, doses, and durations. That heterogeneity, the review authors argued, obscured what probiotics actually add when the underlying regimen is otherwise fixed.

To answer that narrower question, the team searched eight bibliographic databases and three trial registries from inception through mid-July 2026, with no language restrictions. Eligible studies were randomized controlled trials in adults with confirmed H. pylori infection comparing a vonoprazan-based regimen plus a probiotic against the identical regimen without one, with probiotic administration overlapping the eradication course. The searches identified 506 database records and 19 registry records; after screening, sixteen reports corresponding to nine independent randomized studies met the criteria, encompassing 1,270 participants.

All nine trials were conducted in China, one multicenter and eight single-center, published or completed between 2023 and 2026. Six evaluated vonoprazan-amoxicillin dual therapy, one vonoprazan-based triple therapy, and two bismuth-containing quadruple therapy, with treatment durations of 10 days, 14 days, or, in one atypical case, four weeks. The probiotic interventions were biologically diverse, ranging from Bacillus subtilis plus Enterococcus faecium and Saccharomyces boulardii to compound lactic acid bacteria, Bifidobacterium capsules, Bacillus licheniformis, and a Bifidobacterium tetravaccine.

Eradication was generally confirmed by urea breath testing at least four weeks after treatment. Statistically, the team pooled risk ratios using restricted maximum-likelihood random-effects models with Hartung-Knapp confidence intervals, and reported 95 percent prediction intervals to estimate what a future comparable trial might show. The primary outcome was the proportion of participants experiencing at least one adverse event, treated as a participant-level binary measure rather than a count of episodes.

The reviewers used the Cochrane Risk of Bias 2 tool for outcome-specific bias assessments and GRADE to rate certainty, and excluded studies with ambiguous adverse-event totals or serious allocation concerns from the primary analyses. The tolerability signal was striking. Across five studies involving 611 participants, adjunctive probiotics reduced the risk of experiencing at least one adverse event by roughly 70 percent (risk ratio 0.30, 95 percent confidence interval 0.17 to 0.53; P = 0.004), with zero statistical heterogeneity.

The prediction interval, 0.12 to 0.79, remained entirely below the null, suggesting benefit would be expected in a future similar trial. Translated into absolute terms, the risk fell from 261 to about 79 per 1,000 treated, meaning roughly one additional patient avoids an adverse event for every six given probiotics. Sensitivity analyses kept the estimate between 0.31 and 0.38, and GRADE certainty was rated moderate.

The efficacy picture was far less convincing. Intention-to-treat eradication across seven studies and 910 participants showed a small apparent benefit (risk ratio 1.09, 95 percent confidence interval 1.00 to 1.19), but the prediction interval of 0.92 to 1.30 crossed no effect, and statistical significance vanished in sensitivity analyses that excluded dissertation-based or methodologically atypical studies. Per-protocol eradication showed little or no difference (risk ratio 1.03), and adherence, already high at about 95 percent in control groups, was not clearly improved.

Individual symptoms such as constipation, bloating, and nausea trended in probiotics' favor, but these analyses rested on few events and were graded very-low-certainty. Discontinuation and serious adverse events were too rare to yield interpretable estimates. The authors caution that all included trials were conducted in China, and that regional differences in antimicrobial resistance, prior antibiotic exposure, diet, baseline microbiota, probiotic product quality, and symptom-reporting behavior may limit generalizability to other populations.

Most trials were also open-label, a concern for subjectively reported adverse events, and the data cannot identify an optimal probiotic strain, dose, or timing. The reviewers conclude that probiotics are best framed as supportive care to improve tolerability during vonoprazan-based therapy, not as a means of raising cure rates, and they call for adequately powered, placebo-controlled, multicenter trials with standardized outcome definitions and strain-level reporting to confirm the findings in diverse settings.

Subject of Research: Adjunctive probiotics during vonoprazan-based Helicobacter pylori eradication therapy

Article Title: Adjunctive probiotics may reduce adverse events during vonoprazan-based Helicobacter pylori eradication: a systematic review and meta-analysis

Article References: Lin, C.-J., Ren, P.-Y., Chen, H.-Y., Zheng, M.-Q., Jiang, Y.-X., Li, G., Fu, M., & Guo, Y.-H. (2026). Adjunctive probiotics may reduce adverse events during vonoprazan-based Helicobacter pylori eradication: a systematic review and meta-analysis. Frontiers in Pharmacology, 17, Article 1946885. https://doi.org/10.3389/fphar.2026.1946885

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1946885

Keywords: Helicobacter pylori, vonoprazan, probiotics, meta-analysis, adverse events, eradication therapy, gut microbiota, potassium-competitive acid blocker, tolerability, randomized controlled trials, GRADE certainty, gastroenterology

The research team, registered prospectively in the PROSPERO database under identifier CRD420261458417, conducted a comprehensive search of PubMed/MEDLINE, the Web of Science Core Collection, and the Cochrane Central Register of Controlled Trials from database inception through 11 July 2026, with source-specific updates completed on 13 and 14 July 2026. Their question was deceptively simple: among adults treated with the lenvatinib-pembrolizumab combination for advanced or recurrent endometrial cancer, do patients who begin lenvatinib at doses below 20 milligrams fare differently from those who start at the full 20-milligram dose? Because no randomized trial has directly addressed this question, the investigators had to rely on comparative observational studies, a class of evidence that comes with well-known vulnerabilities to confounding and selection bias.

To be eligible, studies had to compare patients on different lenvatinib starting doses within the combination regimen. The researchers defined their primary estimand as the contrast between starting doses below 20 milligrams and the standard 20-milligram starting dose, and they deliberately kept a secondary 10-milligram threshold contrast and a separate measure of relative dose intensity during the first eight weeks of treatment apart from the main analysis, recognizing that pooling these distinct exposure definitions would blur clinically meaningful differences. Binary outcomes such as tumor response and adverse events were summarized as risk ratios, while time-to-event outcomes such as progression-free survival were expressed as hazard ratios. This methodological discipline matters, because dose intensity and starting dose are related but not interchangeable concepts, and conflating them is a common pitfall in dose-optimization research.

The search yielded ten studies representing ten independent cohorts and a total of 1,000 patients. Of these, five cohorts encompassing 703 patients provided data for the primary starting-dose comparison, with the specific denominators varying by outcome depending on how completely each study reported its results. The remaining cohorts informed the secondary contrasts or descriptive syntheses. The scale of the evidence base is modest by the standards of modern oncology, where practice-changing trials often enroll thousands of participants, and this limitation echoes throughout the findings.

The headline result concerns antitumor effectiveness. Pooling across the available cohorts, the risk ratio for objective response, meaning measurable tumor shrinkage, was 0.97 for patients starting below 20 milligrams compared with those starting at 20 milligrams, with a 95 percent confidence interval of 0.70 to 1.34 and minimal heterogeneity between studies, indicated by an I-squared value of 11.9 percent. For disease control, which combines complete responses, partial responses, and stable disease, the pooled risk ratio was 0.96 with a confidence interval of 0.83 to 1.11 and essentially no heterogeneity at all, with I-squared at 0 percent. In plain terms, patients who started at reduced doses appeared to derive neither more nor less tumor control than those who started at the full dose, at least as far as these observational data can tell.

The tolerability picture was equally inconclusive. The pooled risk ratio for subsequent lenvatinib dose reduction, an indirect marker of how often patients needed their doses lowered after starting treatment, was 0.66 with a confidence interval spanning 0.34 to 1.27 and modest heterogeneity of 27.4 percent. Although the point estimate hints that reduced-dose starters needed fewer later dose reductions, the confidence interval crosses 1.0 by a wide margin, meaning the data cannot rule out anything from a substantial benefit to a substantial harm. Estimates for treatment interruption, permanent discontinuation, and grade 3 or higher adverse events were similarly imprecise, and two outcomes of obvious practical importance, hospitalization and treatment persistence, could not be pooled at all because the underlying studies reported them in forms too heterogeneous to combine statistically.

Perhaps the most sobering aspect of the analysis is the quality assessment. The researchers evaluated risk of bias using ROBINS-I, a tool specifically designed for non-randomized studies of interventions, and found that every evaluated result carried a serious overall risk of bias. They used ROB-ME to assess bias arising from missing evidence and applied the GRADE framework to rate certainty, concluding that the certainty of evidence was very low for all pooled comparisons. In the GRADE hierarchy, very low certainty means the true effect could differ substantially from the estimate, and the findings should be regarded as tentative at best. This is not a criticism of the review itself but a reflection of the observational evidence it had to work with: clinicians choose starting doses based on patient characteristics such as body weight, comorbidities, and baseline blood pressure, and those same characteristics independently influence outcomes, creating confounding that statistical adjustment can only partially remove.

The authors’ conclusion is measured but pointed: comparative observational evidence does not establish that starting lenvatinib below 20 milligrams preserves antitumor effectiveness or improves tolerability relative to the standard 20-milligram starting dose. They call for prospective, confounder-aware comparative studies before a reduced starting-dose strategy can be recommended broadly. The distinction between

Subject of Research: Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence

Article Title: Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence

Article References: Wu, Y., Wei, J., Chang, C., Li, M., Xu, R., Dong, S., & Jiang, M. (2026). Lenvatinib starting doses below 20 mg versus 20 mg with pembrolizumab in advanced or recurrent endometrial cancer: a systematic review and meta-analysis of comparative observational evidence. Frontiers in Oncology, 16, Article 1965694. https://doi.org/10.3389/fonc.2026.1965694

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1965694

Keywords: endometrial cancer, lenvatinib, pembrolizumab, dose optimization, meta-analysis, systematic review, immunotherapy, observational evidence, progression-free survival, drug tolerability, oncology, GRADE certainty

Researchers Lele Zhang and Youjie Zhang from China Pharmaceutical University in Nanjing systematically searched six databases—PubMed, Web of Science, Cochrane CENTRAL, CNKI, Wanfang Data, and VIP—for studies published between January 2018 and January 2026 that compared NVBP-selected medicines against their comparators. After screening 2,903 bibliographic records and 862 full-text reports, they identified 81 eligible studies covering more than 40 active ingredients across cardiovascular, anti-infective, psychiatric, endocrine, oncology, gastrointestinal, respiratory, and antiviral therapeutic areas. The review, registered with PROSPERO (CRD420261303351), was conducted according to PRISMA 2020 guidelines and represents the first systematic synthesis of real-world clinical evidence on China’s flagship drug procurement policy.

The central finding is striking in its consistency: across the 69 comparisons in the main analysis—where a procurement-selected generic was compared directly against the originator product—60 of 62 counted efficacy comparisons found no statistically significant difference, and 55 of 65 safety comparisons likewise showed no difference. No efficacy comparison carried an assigned direction favoring either product. This pattern held across drug classes, from atorvastatin and clopidogrel to ceftriaxone and meropenem, from metformin and empagliflozin to bortezomib and pemetrexed. In the largest single study, a 16-hospital matched cohort of over 39,000 atorvastatin users, lipid outcomes were comparable between generic and originator users.

Yet the picture is not uniformly reassuring. Seven safety comparisons did show statistically significant differences: four favored the originator (moxifloxacin tablets, olanzapine, pediatric ceftriaxone, and atorvastatin), while three favored the selected product (linezolid tablets, ceftriaxone, and bortezomib). In three further comparisons, no direction could be assigned because significant findings within a single cohort pointed in opposite directions. Notably, when the analysis was restricted to the 19 multicenter studies, the balance of safety signals reversed—three of the four comparisons retaining a direction favored the selected product rather than the originator, suggesting that the unfavorable signals arose disproportionately from smaller single-center studies.

The review’s methodological rigor is itself a finding. Risk of bias was assessed across eight domains, three of which were developed specifically for this policy setting because no existing instrument captured them. Exposure misclassification emerged as the dominant threat: 21 of the 81 studies began recruitment more than 12 months before the relevant procurement round was announced, meaning patients recorded in the selected-product arm during those periods could not have received a product holding selected status. In one extreme case, recruitment opened nearly nine years before the medicine entered procurement. This dilution of the exposure contrast means the observed concordance of null findings is, to an unquantifiable degree, a comparison of like with like.

Perhaps most sobering is the review’s assessment of what the existing evidence can actually detect. Using the event counts and group sizes reported in the included studies, the authors calculated the smallest difference each comparison could have detected with 80 percent statistical power. The median smallest detectable fall in response rate was 16.5 percentage points, and the median smallest detectable relative risk for harm was 2.67. In practical terms, 17 of 22 efficacy comparisons could not have detected a drop in response rate of less than 10 percentage points, and 19 of 27 safety comparisons could not have detected even a doubling of risk. The concordance of null findings is therefore largely a property of sample sizes rather than a demonstration of equivalence.

The certainty of the evidence, rated using the GRADE framework, was very low for efficacy, safety, and pharmacokinetics, and low for economic outcomes. This is not a bureaucratic formality. An effect estimate was unavailable for 42 of the 81 studies, which reported only a statement of significance or no difference without the underlying data. Sixty-two of the 81 studies were conducted at a single center, and 23 originated from just five research groups or multicenter platforms, meaning the evidence base is less independent than the raw count suggests. Most strikingly, when the authors re-examined 24 included studies against their source articles, six reported test statistics that could not be reproduced from their own summary statistics or counts. In one case, every reported pairing of t and P was arithmetically impossible, and the abstract contradicted the results section.

The review also highlights a distinctive feature of China’s procurement model that sets it apart from generic substitution in the United States, Europe, or Australia. In those settings, substitution typically occurs at the pharmacy level, and patients generally retain the right to request the originator brand. Under NVBP, winning manufacturers receive guaranteed procurement volumes, and non-selected products—including originator brands—may be effectively unavailable within the hospital formulary. Patients and prescribers face a near-complete loss of choice. This mandatory conversion means that any quality or safety signal, even a rare one, reaches a much larger share of the patient population than in voluntary substitution systems, raising the stakes for post-market surveillance.

One pharmacokinetic observation deserves particular attention. In a within-patient study, one procured olanzapine formulation produced a significantly lower dose-corrected steady-state concentration than another procured formulation, even though each had demonstrated bioequivalence to the reference product. Both products were winning suppliers—one from the pilot stage and one from the expansion stage. This finding underscores a fundamental limitation of bioequivalence testing: two products each bioequivalent to a common reference are not thereby bioequivalent to one another, and the intervals permitted by bioequivalence criteria allow a wider separation between two generics than between either and the originator. The authors note that China currently lacks a unified, dynamically updated national narrow therapeutic index catalogue, and they argue that differentiated procurement and monitoring protocols for narrow therapeutic index medicines should be considered a policy priority.

The review’s conclusions are measured. The available evidence does not show that NVBP-selected generics perform worse than their comparators, and this provides cautious reassurance that the policy’s dramatic price reductions have not come at an evident cost to clinical quality. But the authors are equally clear that the concordance of null findings cannot be read as demonstrated equivalence. They call for prospective, adequately powered studies reporting effect estimates with confidence intervals rather than significance tests alone, targeted real-world safety studies for the specific medicines where signals were detected, and product-specific rather than class-wide post-procurement monitoring. They also recommend that future evaluations record the manufacturer and, where feasible, the batch of the dispensed product, since the evidence characterizes individual products rather than classes of procured generics. As the policy enters its renewal phase—with contracts for the first eight rounds renewed nationwide in February 2026—these findings establish both a baseline and a roadmap for the evidence that will ultimately determine whether the world’s largest experiment in centralized drug procurement delivers on its clinical as well as its economic promises.

Subject of Research: Clinical efficacy and safety of generics procured through China's National Volume-Based Procurement policy

Article Title: Clinical efficacy and safety of medicines procured through China’s national volume-based procurement policy: a systematic review of 81 studies

Article References: Zhang, L., & Zhang, Y. (2026). Clinical efficacy and safety of medicines procured through China’s national volume-based procurement policy: a systematic review of 81 studies. Frontiers in Public Health, 14, Article 1820505. https://doi.org/10.3389/fpubh.2026.1820505

Image Credits: AI Generated

DOI: 10.3389/fpubh.2026.1820505

Keywords: China, National Volume-Based Procurement, generic drugs, drug pricing, systematic review, bioequivalence, drug safety, health policy, pharmacovigilance, therapeutic equivalence, narrow therapeutic index, GRADE certainty

Third-wave therapies represent a distinct branch of cognitive-behavioral treatment. Rather than challenging the content of negative thoughts directly, as classical cognitive therapy does, they target underlying processes such as psychological flexibility—the capacity to remain open to difficult experiences while continuing to pursue valued actions. Mindfulness training cultivates present-moment awareness, compassion-focused approaches soften harsh self-criticism, and acceptance and commitment therapy teaches people to detach from unhelpful thoughts instead of fighting them. Delivering these techniques digitally, through smartphone apps, web platforms, and guided online modules, promises scalable mental health care at a fraction of the cost of face-to-face treatment, but the evidence base has been fragmented across hundreds of smaller trials with mixed results.

The new synthesis, prospectively registered on the Open Science Framework and conducted across six databases through January 2026, addressed that fragmentation with rigorous random-effects meta-analysis. The headline numbers are consistent: immediately after treatment, digital third-wave interventions produced standardized effect sizes of g = 0.36 for wellbeing across 46 trials, g = 0.44 for depression across 110 trials, g = 0.40 for anxiety across 93 trials, g = 0.46 for stress across 66 trials, g = 0.30 for quality of life across 32 trials, and g = 0.41 for psychological flexibility across 51 trials. In practical terms, these are small-to-moderate effects—roughly the difference between an average person in the treatment group and someone at the 60th to 65th percentile of the untreated population.

Crucially, the benefits were not confined to any single group. The trials spanned healthy samples (61 trials with 15,770 participants), people with diagnosed mental health conditions (41 trials with 6,130 participants), and medical patients managing physical illness (46 trials with 4,491 participants). When the researchers tested whether population type moderated the immediate effects, it did not reach statistical significance, suggesting that the mechanisms these interventions target—flexibility, acceptance, mindful awareness—operate across the spectrum from prevention to clinical treatment. That universality is precisely what process-based therapeutic models predict, and it strengthens the case for digital delivery as a transdiagnostic tool rather than a condition-specific remedy.

But the analysis also delivered a sobering caveat that the authors emphasize: comparator type significantly moderated several of the pooled results. When digital interventions were tested against active controls—other treatments, attention-matched programs, or credible placebo-like conditions—the effect sizes shrank compared with comparisons against inactive controls such as waitlists. This pattern is familiar from psychotherapy research generally: waitlist comparisons inflate apparent benefits because untreated participants often deteriorate or simply fail to improve, while active comparisons reveal the true incremental value of a specific approach. The authors caution that pooled benefits should therefore be interpreted in relation to comparator intensity, a point that matters enormously for clinicians and policymakers deciding whether to fund digital programs as alternatives to existing care rather than merely as stopgaps for long waiting lists.

Heterogeneity was substantial across most outcomes, with I-squared statistics exceeding 75 percent, meaning that the variability among trial results far exceeded what chance alone would explain. This is not unusual in psychotherapy meta-analyses, but it signals that digital third-wave interventions are not a monolithic entity. Programs differ in duration, intensity, content, delivery format, and the populations they serve, and trial quality varies widely. The substantial heterogeneity underscores why the research team went beyond simple pooling to conduct moderator analyses, probing which design features and contextual factors shaped outcomes rather than treating all interventions as interchangeable.

One of the most practically important findings concerned guidance. Human support—coaching, reminders, or feedback from a trained facilitator—did not significantly moderate immediate post-intervention effects overall, but it did predict larger short-term effects on depression (QM = 4.17, p = .048). This nuanced result suggests that guided and unguided digital programs may perform similarly right away for many outcomes, yet human contact may help consolidate gains for depressive symptoms in the weeks following treatment. For developers of mental health apps, the implication is that fully automated products may be viable for some purposes, but adding even modest human support could meaningfully improve outcomes where depression is the target.

Durability of benefits emerged as another key theme. At short-term follow-up, statistically supported effects remained across all outcomes examined—wellbeing, depression, anxiety, stress, quality of life, and psychological flexibility. At medium-term follow-up, however, only depression, anxiety, and stress retained statistical support, with wellbeing, quality of life, and psychological flexibility no longer distinguishable from controls. This fading pattern raises important questions about whether digital interventions produce lasting changes in the underlying processes they claim to target, or whether participants gradually revert to baseline without ongoing practice or booster sessions. The authors argue that future research should directly test whether improvements in psychological flexibility mediate downstream gains in symptoms and wellbeing—a causal chain that process-based theories assume but few trials adequately verify.

Certainty of the evidence, assessed using the GRADE framework, was moderate for most immediate post-intervention outcomes and low for quality of life, reflecting limitations such as risk of bias, heterogeneity, and imprecision across the included trials. Moderate certainty means the true effect is likely to be close to the estimated effect, giving reasonable confidence in the headline findings, while the low rating for quality of life means those estimates should be treated with more caution. The authors’ recommendations for the field are clear: prioritize rigorous active comparators over waitlist designs, extend follow-up periods well beyond the medium term, and design studies capable of testing the mediating mechanisms that would confirm or refute process-based accounts of how these therapies work.

The broader significance of this analysis lies in what it says about the future of scalable mental health care. With demand for psychological support outstripping the supply of trained clinicians worldwide, digital third-wave interventions offer a genuinely evidence-supported option—not a miracle cure, but a reliable, modest improvement accessible to tens of thousands of people simultaneously. The finding that benefits hold across healthy, clinical, and medical populations, combined with evidence that effects persist at least into the short term for every outcome measured, positions these tools as a meaningful complement to traditional care. At the same time, the shrinkage of effects against active comparators and the fading of some benefits at medium-term follow-up are reminders that the field’s next challenge is not proving that digital mindfulness and compassion programs do something, but establishing exactly how much they add, for whom, and for how long.

Subject of Research: Efficacy of digital third-wave psychological interventions for adult wellbeing and mental health

Article Title: Impacts of digital third-wave interventions for adults on wellbeing and mental health outcomes: A systematic review and meta-analysis of randomized controlled trials

Article References: Gordon, T. C., Kemp, A. H., Hope-Bell, J., & Edwards, D. J. (2026). Impacts of digital third-wave interventions for adults on wellbeing and mental health outcomes: A systematic review and meta-analysis of randomized controlled trials. PLOS Digital Health, 5(10), e0001764. https://doi.org/10.1371/journal.pdig.0001764

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001764

Keywords: digital mental health, third-wave therapies, meta-analysis, mindfulness, acceptance and commitment therapy, compassion-focused therapy, psychological flexibility, randomized controlled trials, depression, anxiety, wellbeing, GRADE certainty

The scale of the problem gives the findings urgency. Chronic kidney disease is defined by structural or functional abnormalities of the kidneys lasting more than three months, or by a decline in the glomerular filtration rate below 60 mL/min/1.73 m². Under the international KDIGO 2012 guidelines, the disease is staged from G1 to G5 by filtration rate and further risk-stratified by albuminuria, with the most advanced cases—those with a filtration rate below 20—requiring renal replacement therapy. Mortality is projected to rise by more than 30 percent between 2022 and 2050, and in Spain, where the review team is based, an estimated one in seven adults lives with the disease, a figure comparable to the United States. Diabetes, hypertension, obesity, cardiovascular disease and age over 60 are the principal risk factors, and lower socioeconomic status compounds the risk.

Quality of life, and specifically health-related quality of life, is the outcome that matters most to patients, yet it is consistently depressed in this population. Compared with healthy individuals, people with chronic kidney disease report reduced physical activity, impaired sexual function, diminished occupational capacity and worse general health, effects that deepen with age and comorbidities. The review’s authors asked a deceptively simple question using the PICO framework: in adults with chronic kidney disease, does health education increase quality of life compared with no education? To answer it, they searched PubMed, the Virtual Health Library and EBSCOhost for studies published between 2014 and 2024, screening 940 records and, after applying inclusion and exclusion criteria, retaining twelve studies for the final synthesis.

The twelve studies fell into four intervention categories that the authors describe as intermediate mechanisms linking education to quality of life: nutrition and fluid management, physical activity, self-management and disease knowledge, and emotional intelligence. Nine were randomized controlled trials, two were quasi-experimental, and one was a single-arm pre-post study. The nutritional trials were among the most revealing. In a randomized trial of 87 hemodialysis patients, individualized dietary advice significantly reduced sodium intake from 90 days onward, along with consumption of packaged seasonings, processed meat and instant noodles, although quality of life itself did not change significantly between groups. Another trial delivered nutrition education virtually, through a Telegram messaging channel, and found that patients not only improved their quality of life but also lowered their serum potassium, sodium, phosphorus and magnesium levels.

The physical activity studies added a striking technological dimension. In the Kidney BEAM trial, 268 patients in the United Kingdom were randomized to a twelve-week digital renal rehabilitation program with live and pre-recorded exercise sessions, or to standard care. The digital group showed significant gains in the mental component of quality of life, patient activation, social function, energy and sit-to-stand performance, and a reduction in the perceived burden of kidney disease—yet the physical component score itself did not change significantly. A Chinese trial of home-based aerobic exercise, by contrast, improved both physical and mental quality of life domains, along with walking capacity, sit-to-stand performance, exercise self-efficacy and anxiety scores. The contrast suggests that intensity and individualization, not the delivery medium, may determine whether physical benefits follow.

Perhaps the most consistent pattern across the synthesis was the divergence between mental and physical improvement. In several studies measuring both components separately—including the digital rehabilitation trial, the self-management program and the peritoneal dialysis retraining study—the mental component of quality of life improved more reliably and to a greater degree than the physical component. The exceptions were instructive: the three studies that found significant gains in both domains combined structured physical activity or nutritional components with individualized, higher-intensity delivery. The authors propose that this differential pattern, rarely addressed explicitly in earlier reviews, reflects the nature of the interventions themselves rather than unexplained inconsistency in the evidence.

Self-management and emotional intelligence programs produced some of the most encouraging results. A twelve-week Australian intervention grounded in social-cognitive theory, combining face-to-face sessions, motivational interviewing and telephone follow-up, improved self-efficacy, disease knowledge, fruit and vegetable consumption and communication with healthcare providers, while reducing alcohol intake, blood pressure and depression and stress scores. In hemodialysis patients, an emotional intelligence program built around self-awareness, self-control, empathy, self-motivation and social skills raised all five domains significantly and improved quality of life at six and twelve weeks. A Bangladeshi trial combining an awareness campaign with mobile health technologies, leaflets and weekly home visits increased disease knowledge and improved blood pressure, body mass index and dietary salinity—though, notably, quality of life measured with the generic EQ-5D-5L instrument showed no significant effect in any analysis.

That last finding points to one of the review’s most practical insights: the choice of measurement instrument matters enormously. In the Kidney BEAM trial, the same patients showed significant improvement on the disease-specific KDQoL-SF questionnaire but not on the generic EQ-5D-5L, suggesting that generic instruments may be less sensitive to change in this population. The authors argue that future trials should adopt validated, kidney-specific quality-of-life measures to avoid false negatives. They also flag findings that did not reach significance rather than burying them: the sodium-restriction trial found no between-group quality-of-life difference, and one Saudi study even reported that the control group scored better on the pain domain of the SF-36, a counter-intuitive result the original publication had not discussed.

The review is candid about the weakness of its evidence base. Applying the Cochrane RoB2 and ROBINS-I tools, the authors rated most studies as having some concerns or high risk of bias, and a simplified GRADE assessment judged the certainty of evidence for the mental component of quality of life to be low and for the physical component very low. Heterogeneity was substantial: six different quality-of-life instruments were used across studies of hemodialysis, peritoneal dialysis and non-dialysis patients, making statistical pooling inappropriate. The review itself was not prospectively registered, was limited to free full-text English and Spanish publications, and could not formally assess publication bias, although the predominance of positive findings raises that possibility. The authors conclude that the results should be interpreted as suggestive rather than conclusive.

Even with those caveats, the direction of the evidence is hard to ignore. Educational interventions were associated with improvements in blood pressure, serum electrolytes, physical function, depression and anxiety in most studies, and patients who received education consistently fared better than those on standard care. The interventions were delivered through remarkably varied channels—Telegram channels, digital rehabilitation platforms, telephone reminders, home visits and bedside counseling—demonstrating that health education can be scaled flexibly and cheaply. The authors note that more frequent and intense interventions produced greater effects, that multidisciplinary teams involving nurses and other professionals could optimize outcomes, and that better-educated patients make more informed decisions about renal replacement therapy. Given that chronic kidney disease already consumes enormous healthcare resources and that its clinical and economic burden is projected to grow through 2027, teaching patients to understand and manage their own disease may prove one of the highest-yield investments available—provided that larger, prospectively registered trials with consistent instrumentation can confirm what these twelve studies only suggest.

Subject of Research: The impact of health education interventions on quality of life in patients with chronic kidney disease

Article Title: Impact of health education on quality of life in patients with chronic kidney disease

Article References: Vicente-Garrido, C., Vicente García, T., Sánchez Aguadero, N., González Sánchez, J., Alonso Domínguez, R., Recio Rodríguez, J. I., Bermejo Gil, B., Coello González, E., & Sánchez-Tocino, M. L. (2026). Impact of health education on quality of life in patients with chronic kidney disease. iScience, 29(10), Article 117555. https://doi.org/10.1016/j.isci.2026.117555

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117555

Keywords: chronic kidney disease, health education, quality of life, systematic review, hemodialysis, patient self-management, nutrition education, physical activity, digital health, emotional intelligence, renal replacement therapy, GRADE certainty

The scale of the underlying problem gives the finding its urgency. According to GLOBOCAN 2022 estimates cited by the authors, esophageal cancer accounts for more than half a million new cases and more than 440,000 deaths annually, with incidence sharply concentrated in Asia where tobacco, alcohol, and nutritional risk factors compound the disease burden. For patients whose tumors are unresectable, recurrent, or metastatic, the historical standard of care, fluoropyrimidine or paclitaxel combined with platinum chemotherapy, has delivered only modest median survival and rarely durable control. That therapeutic ceiling created a strong biological rationale for moving immune checkpoint inhibition into the frontline, and ESCC proved an especially receptive target because it more often presents an inflamed tumor microenvironment and clinically relevant PD-L1 expression than esophageal adenocarcinoma.

Conducting a trustworthy synthesis across the new wave of trials, however, demanded unusual methodological care. The research team searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science from January 2015 through April 2025, following the PRISMA 2020 reporting framework. From 416 initial records, screening and full-text review narrowed the field to seven studies: six entered the primary pooled analysis and one, the biomarker-restricted ASTRUM-007 trial, was held back for sensitivity analysis because it enrolled only PD-L1-positive patients. A seventh candidate, GEMSTONE-304, was excluded outright because it tested PD-L1 blockade rather than PD-1 blockade, a distinction the authors treated as biologically meaningful rather than semantic.

The six primary trials form a who’s-who of modern esophageal oncology: KEYNOTE-590, from which only the prespecified squamous cell carcinoma subgroup was extracted to avoid contaminating the analysis with adenocarcinoma data; CheckMate-648, contributing its nivolumab-plus-chemotherapy arm; and the ESCORT-1st, JUPITER-06, ORIENT-15, and RATIONALE-306 studies, several of them conducted predominantly in China. Every single trial reported an overall survival advantage for the immunotherapy-containing regimen. Individual hazard ratios ranged from 0.58 for toripalimab plus paclitaxel and cisplatin in JUPITER-06 to 0.74 for nivolumab plus fluoropyrimidine and cisplatin in CheckMate-648, with pembrolizumab, camrelizumab, sintilimab, and tislelizumab regimens falling in between. When these estimates were combined using a fixed-effect inverse-variance model, the result was a hazard ratio of 0.68 with an I-squared statistic of zero percent.

That homogeneity statistic deserves attention because it is the technical heart of the paper’s credibility. I-squared quantifies what proportion of variability between study results is due to genuine differences rather than chance, with values above 75 percent conventionally labeled considerable heterogeneity. A value of zero across six trials testing five different PD-1 antibodies on multiple chemotherapy backbones, in populations spanning global and China-focused recruitment, suggests the survival benefit is a property of the drug class itself rather than an artifact of any single regimen or region. The authors nonetheless interpreted this cautiously, noting that I-squared loses precision when fewer than ten studies are pooled, and they ran random-effects and sensitivity analyses as robustness checks. Adding ASTRUM-007 changed nothing: the pooled estimate remained 0.68 with the same confidence interval, and the estimated between-study variance was zero.

The evidence quality assessment reinforced the headline result. Using the Cochrane RoB 2 tool, two independent reviewers judged five of the six primary trials at low overall risk of bias, with CheckMate-648 raising some concerns due to its open-label design and potential deviations from intended interventions. Under the GRADE framework, certainty for the overall survival outcome was rated high, reflecting phase III randomized data with consistent direction of effect, a precise pooled estimate, and minimal heterogeneity. Safety certainty was rated moderate because adverse-event definitions were not harmonized across trials, and certainty for biomarker-defined subgroups ranged from low to moderate owing to indirectness and imprecision.

That last point, biomarker interpretation, is where the analysis delivers its most clinically sobering nuance. The trials measured PD-L1 with fundamentally incompatible tools: some used the combined positive score, others tumor proportion score or tumor-area positivity, and several reported only exploratory analyses. Because quantitative pooling was impossible, the authors synthesized subgroup findings narratively, and the picture that emerges is one of attenuation at the biomarker-negative end. KEYNOTE-590 suggested diminished benefit in patients with CPS below 10, ORIENT-15 found no clear benefit in its small CPS-below-1 subgroup, and an external meta-analysis by Beshr and colleagues, incorporating CPS subgroup data presented at the September 2024 FDA Oncologic Drugs Advisory Committee meeting, similarly found no evident overall survival benefit in the CPS-below-1 population while benefit was greatest at CPS 10 or above. PD-L1, in other words, is not a universal binary gatekeeper, but the evidence base is weakest precisely where clinicians most need guidance: patients with low or negative expression.

Safety findings add a second layer of practical nuance. Grade 3 or higher treatment-related adverse events ranged from 47 to 72 percent in the immunotherapy arms and 36 to 68 percent in control arms, a reminder that platinum doublets are inherently toxic regardless of what is added to them. The distinctive contribution of PD-1 inhibitors is not a wholesale escalation of overall toxicity but the introduction of a new category of immune-mediated events, including hypothyroidism, rash, hepatitis, pneumonitis, and colitis. Most of these proved manageable with established treatment algorithms, but the authors emphasize that survival gains come with a corresponding obligation: earlier recognition of endocrine, pulmonary, hepatic, and gastrointestinal immune toxicities, multidisciplinary collaboration, and thorough patient education.

The clinical implications are direct. For fit patients with advanced or metastatic ESCC, the data support PD-1 inhibitor-based chemoimmunotherapy as a frontline standard, a position contemporary guidelines have already begun to reflect, though they differ in how strongly they tie specific agents to PD-L1 thresholds. The authors also caution that treatment choice should be contextualized by chemotherapy backbone, regulatory label, and local access, since the trials varied in these respects even as the relative effect remained constant. Notably, the revision corrects methodological flaws that have distorted earlier syntheses, avoiding mixed-histology overall estimates from KEYNOTE-590 and refusing to conflate CheckMate-648’s chemotherapy-free nivolumab-plus-ipilimumab arm with chemotherapy-containing regimens.

The study’s limitations are candidly acknowledged: it is a literature-based rather than individual-patient-data meta-analysis, biomarker subgroup reporting was too inconsistent for formal pooling, safety endpoints were synthesized narratively, and the review was not prospectively registered in PROSPERO. The authors also verified published journal corrections for at least two pivotal trial reports and confirmed no retractions among the key primary publications. What remains is a finding that will be difficult to dislodge: across every modern phase III trial conducted to date, adding a PD-1 inhibitor to frontline chemotherapy has extended survival in advanced esophageal squamous cell carcinoma, and the effect is as statistically uniform as oncology evidence rarely gets. The unfinished business is precision, determining which patients with minimal PD-L1 expression truly benefit, and ensuring that the assays used to measure that expression finally speak the same language.

Subject of Research: First-line PD-1 inhibitor-based chemoimmunotherapy versus chemotherapy alone for advanced or metastatic esophageal squamous cell carcinoma

Article Title: First‐Line PD‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials

Article References: Rothweiler, V., Roderburg, C., Koeksal, M., Jensen, B. E. O., Feldt, T., Gencer, I., Fischer, J. C., Budach, W., Knoefel, W. T., Lu, G., & Bölke, E. (2026). First‐Line PD ‐1 Inhibitor‐Based Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Revised Systematic Review and Meta‐Analysis of Phase III Trials. Cancer Reports, 9(9), Article e70660. https://doi.org/10.1002/cnr2.70660

Image Credits: AI Generated

DOI: 10.1002/cnr2.70660

Keywords: esophageal squamous cell carcinoma, PD-1 inhibitors, immunotherapy, meta-analysis, overall survival, PD-L1, phase III trials, chemoimmunotherapy, pembrolizumab, nivolumab, checkpoint inhibitors, GRADE certainty

The research team searched five major databases—PubMed, Embase, Scopus, Web of Science and the Cochrane Central Register—through November 2025, screening more than 2,400 records under PRISMA 2020 guidelines. From that effort, eight unique studies contributing ten distinct comparisons made the final synthesis. Five comparisons came from propensity score-matched observational cohorts, four from nonmatched cohorts, and one from randomized trial data, including prespecified analyses of the FLOW and SOUL trials. The researchers deliberately excluded studies that reported only composite major adverse cardiovascular events, or MACE, insisting instead on separate data for myocardial infarction and stroke—a decision that proved scientifically decisive.

That insistence matters because composite endpoints have long been a blind spot in cardiovascular outcomes research. Myocardial infarction is fundamentally a coronary atherothrombotic event, driven by plaque rupture and clot formation in the heart’s arteries, while stroke is a heterogeneous condition involving both cerebrovascular atherosclerosis and cardioembolic pathways. Pooling these biologically distinct events into a single MACE score can mask divergent treatment effects, much like averaging the temperatures of two different cities. By disaggregating the endpoints, the researchers could ask a sharper question: does dual therapy protect the coronary arteries and the cerebral circulation equally?

The answer, intriguingly, is no. For myocardial infarction, combination therapy was associated with a pooled hazard ratio of 0.79, meaning a 21 percent relative risk reduction compared with monotherapy overall. Yet when the investigators stratified by comparator, a telling pattern emerged: dual therapy significantly outperformed SGLT2 inhibitor monotherapy for MI prevention (hazard ratio 0.74), but showed no statistically significant advantage over GLP-1 receptor agonist monotherapy (hazard ratio 0.80, confidence interval 0.55 to 1.16). In other words, the coronary benefit appears to be carried almost entirely by the GLP-1 receptor agonist component of the combination.

This finding aligns closely with the biology established by landmark cardiovascular outcome trials. GLP-1 receptor agonists exert robust antiatherosclerotic and antiinflammatory effects—improving endothelial function, plaque stability, body weight and blood pressure—making them particularly well suited to preventing atherothrombotic coronary events. In the HARMONY Outcomes trial, for instance, the GLP-1 agonist albiglutide reduced MACE, and among the individual components only myocardial infarction showed a statistically significant reduction. SGLT2 inhibitors, by contrast, deliver their most profound and reproducible benefits in heart failure and kidney protection, with more modest effects on atherosclerotic events. Adding an SGLT2 inhibitor to a patient already on a GLP-1 agonist may therefore offer limited incremental defense against coronary ischemia, because the atherothrombotic pathways are already being substantially modulated.

Stroke told a different and arguably more exciting story. Combination therapy was associated with a 15 percent lower stroke risk overall (hazard ratio 0.85), and unlike the MI findings, this benefit outperformed both individual drug classes: a 27 percent reduction versus SGLT2 inhibitor monotherapy and a statistically significant 8 percent reduction versus GLP-1 receptor agonist monotherapy. The advantage was concentrated in ischemic stroke specifically, with a hazard ratio of 0.67. The researchers propose a dual-pathway synergy: while the GLP-1 agonist stabilizes the cerebrovascular wall against atherosclerosis, the SGLT2 inhibitor contributes hemodynamic offloading, blood pressure lowering and possible antiarrhythmic effects. Supporting this framework, prior mechanistic studies have shown that combining the two agents improves endothelial glycocalyx integrity, pulse wave velocity, central systolic blood pressure and left atrial strain—parameters directly relevant to cardioembolic stroke risk.

Perhaps the most clinically provocative result was the age interaction. The cerebrovascular benefit appeared dramatically stronger in adults aged 65 and older, who showed a remarkable 50 percent relative reduction in stroke risk (hazard ratio 0.50), an effect absent in younger cohorts. The authors note that older adults carry a higher baseline burden of arterial stiffness, chronic kidney disease and occult atrial arrhythmias—pathophysiological domains where combined vascular and cardiorenal risk reduction may yield the greatest absolute benefit. However, they caution that this age-related signal, though statistically significant, rests on a limited number of comparisons and could reflect chance.

The analysis was not without warning signs. Substantial heterogeneity characterized both endpoints, with I-squared values of 72.8 percent for MI and 63.5 percent for stroke. Sensitivity analyses revealed that nonmatched observational cohorts produced a larger MI association (hazard ratio 0.67) than propensity-matched comparisons (hazard ratio 0.87), a statistically significant difference that suggests residual confounding and treatment-selection bias may inflate the apparent benefit in less rigorous study designs. One exploratory subgroup even showed elevated stroke risk among baseline insulin users (hazard ratio 2.33), though this rested on a single comparison and may simply reflect confounding by indication, since insulin use often marks more advanced disease. Applying the GRADE framework, the researchers rated the overall certainty of evidence as very low for both endpoints.

The authors are emphatic that these findings are hypothesis-generating rather than practice-changing. Current American Diabetes Association guidelines already recommend tailoring therapy to individual cardiovascular risk profiles, and both drug classes are well established individually; the new analysis does not mandate dual therapy solely for MI or stroke prevention. Instead, the results suggest that when both agents are already clinically appropriate for a patient’s broader cardiometabolic needs—glycemic control, weight management, heart failure risk—the potential for vascular-specific protection adds a further rationale. Notably, the safety profile of the combination appears favorable, with adverse events remaining largely class-specific: genital mycotic infections and rare euglycemic ketoacidosis for SGLT2 inhibitors, gastrointestinal intolerance for GLP-1 agonists, and a need for careful insulin adjustment to avoid hypoglycemia.

What the field needs next, the researchers argue, are dedicated prospectively powered randomized trials designed from the outset to compare combination therapy against active monotherapy, powered for individual coronary and cerebrovascular events rather than composite MACE. Such trials should capture stroke subtypes, fatal versus nonfatal events, and the sequencing question of simultaneous initiation versus sequential add-on. Until then, this meta-analysis offers a compelling physiological preview: two blockbuster drug classes, each famous in its own right, may protect the heart and the brain through complementary, nonredundant mechanisms—and the patients who stand to gain the most from putting them together may be older adults at high cerebrovascular risk.

Subject of Research: The effect of combined SGLT2 inhibitor and GLP-1 receptor agonist therapy on myocardial infarction and stroke risk in adults with type 2 diabetes

Article Title: Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis

Article References: Ghafoury, R., Naghshbandi, M., Malek, M., Kalra, S., Ismail-Beigi, F., & Khamseh, M. E. (2026). Effect of Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists on Myocardial Infarction and Stroke in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-026-01911-2

Image Credits: AI Generated

DOI: 10.1007/s13300-026-01911-2

Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, type 2 diabetes, myocardial infarction, stroke, combination therapy, meta-analysis, cardiovascular outcomes, Diabetes Therapy, ischemic stroke, cardiometabolic medicine, GRADE certainty